The Ac225 is extracted using commercial resins for separation. They are capable of producing 1 mCi batches now and expect to scale up to 100 mCi/week by 2025. The company has obtained an NRC license to irradiate the Ra target and extract Ac225. They are currently seeking partners for producing Abasedaseed pharmaceutical compounds.
Presented by: Terry Grimm, MD, Niowave, Inc., Lansing, Michigan, United States
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada